Avadel Pharmaceuticals plc, who is developing FT218, an investigational, once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy, announced that they have completed the REST-ON Phase 3 clinical trial for FT218. Overall, the study enrolled a total of 212 patients. Avadel hopes to announce topline data from the study in the second quarter of 2020.

The REST-ON study was a double-blind, randomized, placebo-controlled Phase 3 trial whose goal was to measure the efficacy and safety of FT218. 

To read more about this trial and FT218, see Avadel’s full press release.